NEW YORK (GenomeWeb News) — Mirus Bio has received a two-year, $900,000 Phase II Small Business Innovative Research grant to develop its microRNA-labeling technology for clinical research and “potential diagnostic applications,” the company said today.
The Madison, Wis.-based miRNA and siRNA transfection company said it will use the money to develop products that will study the link between miRNAs and undisclosed diseases that it will eventually “enable diagnostic testing for miRNAs as biomarkers for disease.”

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A draft bill released by the US House of Representatives appropriations committee would increase the 2019 National Institutes of Health budget by 3 percent.

Bloomberg looks into privacy issues raised by law enforcement's use of genetic genealogy sites.

NBC News reports on the Earth BioGenome Project, which aims to sequence all eukaryotic life on Earth.

In Science this week: environmental DNA can help in studies of marine animals, and more.

Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.